Devlin, NJ, Sussex, J. Incorporating multiple criteria in HTA: Methods and processes. London: Office of Health Economics; 2011.
Douma, KF, Karsenberg, K, Hummel, MJ, Bueno-de-Mesquita, JM, van Harten, WH. Methodology of constructive technology assessment in health care. Int J Technol Assess Health Care. 2007;23:162–168.
Marsh, K, Ganz, M, Hssu, J, et al.
Health technology assessment and environmental costs: Time for health care to catch up?
Value Health. 2014;17:A586.
NHS Sustainable Development Unit. Saving carbon, improving health. Update - NHS Carbon Reduction Strategy. Cambridge: Sustainable Development Unit.
Swedish Medical Products Agency. National drug strategy – Action plan. Uppsala, Sweden: Swedish Medical Products Agency; 2011.
Marsh, K, Ganz, M, Hssu, J, et al.
Expanding health technology assessments to include effects on the environment. Value Health. 2016;19: 249–254.
Tanios, N, Wagner, M, Tony, M, et al.
Which criteria are considered in healthcare decisions? Insights from an international survey of policy and clinical decision makers. Int J Technol Assess Health Care. 2013;29:456–465.
IPCC. Human health: Impacts, adaptation, and co-benefits. In: Climate Chate 2014: Impacts, adaptation, and vulnerability. Geneva: Intergovernmental Panel on Climate Change; 2014.
Costello, A, Abbas, M, Allen, A, et al.
Managing the health effects of climate change. Lancet. 2009;373:1693–1733.
Briggs, D. Environmental pollution and the global burden of disease. Br Med Bull. 2003;68:1–24.
Practice Greenhealth. Healthcare energy impacts calculator. Reston, VA: Practice Greenhealth; 2008.
Larsen, HN, Solli, C, Pettersena, J.
Supply chain management–How can we reduce our energy/climate footprint?
Energy Procedia. 2012;20:354–363.
NHS Sustainable Development Unit. Goods and services carbon hotspots: NHS England breakdown of goods and services carbon footprint by organisation type (Full Report). UK: NHS Shared Business Services; 2012.
National Institute for Health and Care Excellence. Type 2 diabetes: The management of Type 2 diabetes. NICE clinical guideline 87. 2009; Modified 2014. London: National Institute for Health and Care Excellence; 2014.
Palmer, AJ, Roze, S, Valentine, WJ, et al.
The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004;20
McEwan, P, Foos, V, Palmer, JL, et al.
Validation of the IMS CORE Diabetes Model. Value Health. 2014;17:714–724.
NICE. Process and methods guides: Guide to the methods of technology appraisal 2013, National Institute for Health and Care Excellence, Editor. London, UK: National Institute for Health and Care Excellence; 2013.
Fritsche, A, Schweitzer, MA, Haring, HU. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med.
Pratley, RE, Nauck, M, Bailey, T, et al.
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: A 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375:1447–1456.
Morris, DS, Wright, T, Somner, JE, Connor, A. The carbon footprint of cataract surgery. Eye (Lond). 2013;27:495–501.
Connor, A, Lillywhite, R, Cooke, MW. The carbon footprint of a renal service in the United Kingdom. QJM. 2010;103:965–975.
The Social Costs of Carbon (SCC) review – Methodological approaches for using SCC estimates in policy assessment: Final report. Department for Environment, Editor. Norwich, UK: Office of Public Sector Information; 2005.
Estimates of the social cost of carbon: Background and results from the RICE-2011 model. Cambridge, MA: National Bureau of Economic Research; 2011.
Davies, MJ, Chubb, BD, Smith, IC, Valentine, WJ. Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus. Diabet Med. 2012;29:313–320.